Esperion was founded in April 2008 by former executives of, and investors in, the original Esperion Therapeutics, Inc. The original Esperion was a biopharmaceutical company which was primarily focused on the research and development of therapies to regulate high-density lipoprotein cholesterol, or HDL-C. After successfully completing a Phase 2a clinical trial with its synthetic HDL therapy, the original Esperion was acquired by Pfizer Inc. in 2004. ETC-1002 was first discovered at the original Esperion, and we subsequently acquired the rights to it from Pfizer in 2008. We own the exclusive worldwide rights to ETC-1002.
Our name encapsulates the Esperion spirit:
Esprit de corps: Our common spirit inspires enthusiasm, devotion, and cooperation.
Esperance: Hope is what we give to individuals who suffer from cardiovascular and metabolic diseases.
-ion: This suffix means “activity” or “resulting from” represents our dedication to activities, teamwork, and cutting edge technologies that result in the discovery and development of new therapies for unmet medical needs.